Tech Company Financing Transactions
Adcendo Funding Round
Adcendo, based in Copenhagen, secured $33.8 million in investment from Gilde Healthcare Partners, Healthcap Venture Capital and Novo Holdings.
Transaction Overview
Company Name
Announced On
4/4/2023
Transaction Type
Venture Equity
Amount
$33,832,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to initiate a broad clinical development program for uPARAP ADC in Sarcoma and is also planning to advance the development of its 2nd ADC pipeline asset with Development Candidate Nomination (DCN) planned in H1 2024.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
BioInnovation Institute, Ole Maaløes Vej 3, Copenhagen, Capi
Copenhagen, 2200
DK
Copenhagen, 2200
DK
Phone
Undisclosed
Website
Email Address
Overview
Adcendo ApS is a Copenhagen-based biotech company dedicated to developing highly differentiated antibody-drug conjugates (ADCs) for the treatment of underserved cancers. Antibody-drug conjugates (ADCs) represent an emerging drug modality, directing anticancer therapeutics to malignant cells overexpressing particular surface target molecules. 10+ ADCs are now in routine clinical use for cancer patients, with many more novel ADC assets currently investigated in clinical studies in solid tumors and hematologic malignancies
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 4/4/2023: Everstream Analytics venture capital transaction
Next: 4/4/2023: Trustle venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs